Proactive Investors - Run By Investors For Investors

Riccardo Lowi discusses Evgen Pharma

Riccardo Lowi analyst at Capital Network talks through Evgen Pharma that has developed a proprietary technology - Sulforadex® - that allows the synthesis of sulforaphane in the form of a stable, solid powder that can be easily manufactured as an oral drug.

 
View full EVG profile View Profile

Evgen Pharma Timeline

Newswire
December 12 2018
CN Video
March 07 2018
Article
October 21 2015

Related Videos

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use